MORE►
machine learning
ConcertAI CEO Jeff Elton (left) and David Spetzler, president of Caris Life Sciences [Photo: ConcertAI]
Caris Life Sciences and ConcertAI Announce New Clinico-Genomic Research Platform
by Lance Murray | Jun 1, 2023
Expanding a collaboration they announced in January, the two companies aim to drive "the future of cancer care" with the new platform, enabling novel insights for precision medicine, therapeutic development, and clinical trials management for academic and biopharma researchers.
by Lance Murray |
May 2, 2023
The "blood-brain barrier" acts like a highly selective firewall, preventing an estimated 98% of drugs from entering the brain—making it a major hurdle in the development of brain and central nervous system drugs. Lantern Pharma has recently developed what it calls "highly accurate AI algorithms" to predict the ability of a drug or compound to pass through the barrier.
MORE►
by Lance Murray |
Mar 28, 2023
The Southlake-based company says retailers can sign up and use what it calls the industry's most powerful, accurate AI and ML-driven metric forecasting through a fully automated self-serve platform—all at no obligation. "We're confident retailers will be intrigued and delighted when they compare our automated forecast results with their actuals and legacy forecasts," says Founder and CEO Purna Mishra.
MORE►
by Lance Murray |
Mar 2, 2023
Dallas-based Lantern Pharma Inc. has expanded its clinical development team with the addition of Dr. Reggie Ewesuedo as vice president of clinical development, and several additional team members....
MORE►
Lantern Pharma CEO Panna Sharma [Courtesy: Lantern Pharma]
Lantern Pharma’s New Drug Candidate for Mantle Cell Lymphoma Shows Promise
by Quincy Preston | Dec 22, 2022
The Dallas-based biopharmaceutical company expects to begin testing the drug candidate in a “first in human” trial in mid-2023. The drug was developed using the publicly traded company’s AI/ML drug development platform.
Lantern, in collaboration with the National Cancer Institute, recently published insights on how AI can be used to find new indications for cancer drugs in record times with significant reductions in costs.
Lantern, in collaboration with the National Cancer Institute, recently published insights on how AI can be used to find new indications for cancer drugs in record times with significant reductions in costs.
MORE►
![From left: Abidali Neemuchwala and Dayakar Puskoor [Photo: Dallas Venture Capital]](https://s24806.pcdn.co/wp-content/uploads/2022/05/DVC-Abidali-Neemuchwala-DayakarPuskoor-360x203.jpg)
by Kevin Cummings |
May 25, 2022
Dallas Venture Capital is "poised to bootstrap two large start-up ecosystems in the U.S. and India," says co-founder Dayakar Puskoor.
The venture firm—which has an office in Irving and another in Hyperabad, India—plans a combined deployment of the funds over four to five years.
The venture firm—which has an office in Irving and another in Hyperabad, India—plans a combined deployment of the funds over four to five years.
MORE►
by Kevin Cummings |
May 11, 2022
Dallas-based software startup HireLogic aims to improve the job interview process with its AI- and machine learning-powered platform, designed to help automate the screening process. Its CEO says he wants to help companies "gain insights from interview data to make faster, better hiring decisions."
MORE►
by Kevin Cummings |
Apr 5, 2022
The investment from London-based online luxury retail marketplace Farfetch makes it a new minority owner of Neiman Marcus Group. It will also be a partner, helping NMG expand its reach globally via digital customer experiences and curated offerings on Farfetch’s platform.
MORE►
In the SMU study on Dallas' infrastructure deserts, neighborhoods seen in dark red are "highly deficient." Circles denote predominant race-ethnicity (blue for white, green for black, reddish for Hispanic, purple for no predominance). [Image: SMU]
SMU Study Uses Drones and Machine Learning to Find ‘Infrastructure Desert’ Neighborhoods in Dallas
by David Seeley | Feb 22, 2022
The study by a team of SMU civil engineering researchers was supported by a five-year, $584,000 National Science Foundation grant. The team hopes that their study will lead to equitable improvements in the identified neighborhoods—with better groceries, internet access, noise walls, crosswalks, hospital access, bike trails, and more.
MORE►
by Kevin Cummings |
Feb 16, 2022
New York-based Bowery Farming is a vertical farming startup that aims to lead "the next generation of agriculture." Valued at $2.3 billion and backed by Alphabet's VC investment arm GV, it will create 100 jobs at its new indoor farm in Arlington—where software, sensors, and machine learning will help things grow.
MORE►
by Kevin Cummings |
Feb 7, 2022
McKinney-based BALANCED Media|Technology, SMU, and the Retina Foundation of the Southwest are collaborating to commercialize technology to fight age-related macular degeneration.
Using a crowdsourced video game, players help the team create new data sets out of captured retinal images, helping to lead to potential breakthroughs in detection and treatment.
MORE►
by David Seeley |
Nov 11, 2021
SMU is investing $11.5 million into a powerful new supercomputing research system featuring an NVIDIA DGX SuperPOD. Connected with the NVIDIA Quantum InfiniBand networking platform in SMU's data center, it will produce a theoretical 100 petaflops of computing power—enabling the university's network to perform "a blistering 100 quadrillion operations per second."
The new capability will supercharge SMU's AI and supercomputing exploration, boosting North Texas' growth as a technology hub.
MORE►
14 Emerging Tech Trends for 2021—and Dallas-Area Companies That Are Innovating for the Future
by Quincy Preston and Sandra Engelland | Feb 23, 2021
From ABIA to Zyvex, Dallas-Fort Worth companies are at the forefront of innovations in AI, 5G, quantum computing, genomics, and more.
MORE►
A UT Southwestern Machine Learning Algorithm Finds COVID-19 Cases Significantly Higher Than Reported
by Lauren Hawkins |
Feb 8, 2021
Researchers in the Lyda Hill Department of Bioinformatics have estimated that the amount of COVID-19 cases is nearly triple those confirmed in the U.S.
MORE►
by Sandra Engelland |
Jan 13, 2021
The company’s six patent-pending frameworks are at the heart of its success, helping clients increase revenue, efficiency, and usable information.
MORE►
by Alex Edwards |
Nov 18, 2020
Lantern Pharma amassed 1 billion data points on its proprietary artificial intelligence platform, which it believes is the most of any company in biotech. Now, the company is able to reduce cost, time, and risk to establish a more sustainable route in oncology drug development.
MORE►
